Ipamorelin and CJC-1295 are the classic growth-hormone peptide pairing, and they're frequently discussed together because they work through different, complementary receptors. Ipamorelin is a GHRP — it mimics ghrelin to trigger a pulse of growth hormone, and is prized for being "clean" (little effect on cortisol, prolactin or appetite). CJC-1295 is a GHRH analog that amplifies the size of the natural GH pulse and, in its DAC form, extends its duration. Neither is an approved medicine; both are research chemicals banned in sport.
At a glance
| Ipamorelin | CJC-1295 | |
|---|---|---|
| Class | GHRP (ghrelin/GH-secretagogue-receptor agonist) | GHRH analog |
| Mechanism | Triggers a GH pulse | Increases GH pulse amplitude (and duration with DAC) |
| Selectivity | Selective — minimal cortisol/prolactin/appetite effect | Acts on the GHRH receptor |
| Duration | Short-acting | Short (no-DAC) or long-acting (with DAC) |
| FDA status | Not approved (research chemical) | Not approved (research chemical) |
| Sport status | Banned (WADA) | Banned (WADA) |
| Often used | Frequently paired with a GHRH analog | Frequently paired with a GHRP like ipamorelin |
The bottom line
Bottom line: These aren't really rivals — they're two halves of a system. Ipamorelin (a GHRP) and CJC-1295 (a GHRH analog) act on separate receptors, which is exactly why they're so often combined to produce a larger GH response than either alone. The shared reality is that neither is approved, human outcome data are limited, and both are banned in sport.
Frequently asked questions
What is the difference between ipamorelin and CJC-1295?
Ipamorelin is a GHRP that triggers a growth-hormone pulse by mimicking ghrelin, while CJC-1295 is a GHRH analog that increases the size (and, with DAC, the duration) of that pulse. They act on different receptors.
Why are ipamorelin and CJC-1295 used together?
Because they work through complementary pathways — a GHRP plus a GHRH analog — combining them can produce a larger growth-hormone release than either alone. This is the rationale behind the popular pairing, though human evidence is limited.
Is ipamorelin or CJC-1295 safer?
Ipamorelin is considered 'cleaner' because it has minimal effect on cortisol, prolactin and appetite, but long-term human safety data are lacking for both. Neither is FDA-approved, and both are banned in sport.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. Peer-reviewed study
- Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: growth hormone secretagogues in the management of body composition in hypogonadal males. Transl Androl Urol. 2020. Peer-reviewed study
- Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999. Peer-reviewed study
- Lu Z, Ngan MP, Liu JYH, et al. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiol Behav. 2024. Peer-reviewed study
- Gouda M, Ganesh CB. The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. Anim Reprod Sci. 2024. Peer-reviewed study
- Gobburu JV, Agersø H, Jusko WJ, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. Peer-reviewed study
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. Peer-reviewed study
- Jette L, Leger R, Thibaudeau K, et al. hGRF(1-29)-albumin bioconjugates activate the GRF receptor: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. Peer-reviewed study
- Timms M, Ganio K, Steel R. A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. Drug Test Anal. 2019. Peer-reviewed study
- Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse. 2016. Peer-reviewed study
- Timms M, Ganio K, Forbes G, et al. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug Test Anal. 2019. Peer-reviewed study
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006. Peer-reviewed study